

ASX RELEASE

14 October 2021

AMPLIA RECEIVES \$1.1m R&D TAX INCENTIVE

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) wishes to advise that it has received a Research and Development Tax Incentive Refund of \$1,140,352.91 for the 2020/2021 financial year. The refund recognizes expenditure incurred in research and development associated with the Company’s FAK inhibitors, AMP945 and AMP886.

These R&D activities primarily relate to the Company’s Phase 1 clinical trial of AMP945 in healthy volunteers which was completed during the first half of this year and associated preparatory works.

The Australian Government’s Research and Development Tax Incentive Refund provides eligible companies with cash refunds for 43.5% of eligible expenditure on research and development activities.

This ASX announcement has been approved and authorised for release by the CEO of Amplia Therapeutics.

- End -

For Further Information

Dr. John Lambert

CEO and Managing Director

john@ampliatx.com

www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).